Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887650 · ClinicalTrials.gov registry record · Phase 4
LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs
A Phase 4 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT03887650: Completed Phase 4 study, sponsored by Hartford Hospital.
NCT03887650 is a Phase 4 study that has completed, run by Hartford Hospital. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03887650, a Phase 4 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total opioid consumption in the first three post-operative days.
Primary Outcome
Total opioids used for the first 120 postoperative hours after TSA, standardized to morphine milligram equivalents (MMEs)
Interventions
- DRUG Bupivacaine 0.5%
- DRUG Liposomal Bupivicaine 1.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-03-08 |
| Phase | Phase 4 |
What the finished NCT03887650 record still lists
NCT03887650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine 0.5% is the first listed.
NCT03887650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03887650 about?
NCT03887650 is a clinical study titled "LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs". This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total...
What is the current status of trial NCT03887650?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2019-03-11. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT03887650?
The interventions under investigation include: Bupivacaine 0.5% (DRUG), Liposomal Bupivicaine 1.3% (DRUG).
Who is sponsoring clinical trial NCT03887650?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03887650's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI